Imran Nizami

Imran Nizami

Auto-generated profile, based on publicly available information

Imran Nizami

Lung Transplant Section, Organ Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Metabolomics
Verified
Journal Article
Closed access
PDF file
AMAfshan Masood
Afshan Masood
MJMinnie Jacob
Minnie Jacob
XGXinyun Gu
Xinyun Gu
MJMai Abdel Jabar
Mai Abdel Jabar
HBHicham Benabdelkamel
Hicham Benabdelkamel
ARAnas Abdel Rahman
Anas Abdel Rahman

1 January 2021 in Experimental and Clinical Transplantation
Verified
Journal Article
Closed access
DADema Alissa
Dema Alissa
RAReem AlMaghrabi
Reem AlMaghrabi
INImran Nizami
Imran Nizami
ASAmal Saleh
Amal Saleh
ASAmjad Al Shamrani
Amjad Al Shamrani
GKGhazwa B. Korayem
Ghazwa B. Korayem
Lung transplant guidelines recommend nebulized amphotericin B with or without systemic antifungal agents for fungal prophylaxis. However, amphotericin formulation, dosing, and frequency vary between studies. We assessed the safety and effectiveness of nebulized amphotericin B to prevent Aspergillus infection in 2 regimens, ie, twice daily compared with 3 times daily. This was a single-center retrospective cohort study. We included patients at least 14 years old who underwent lung transplant and received nebulized amphotericin B alone or in combination with another antifungal agent either twice daily or 3 times daily. The primary endpoint was the incidence of lung Aspergillus infection, and the secondary endpoints were nebulized amphotericin B side effects and breakthrough Aspergillus infection. A total of 84 patients were included. The group given nebulized amphotericin twice daily had a higher rate of Aspergillus infection at 17% compared with 4% in the group treated 3 times daily (P = .24). No serious side effects were reported, but coughing and diarrhea were more common in patients who received amphotericin B 3 times daily. A systemic antifungal agent combined with nebulized amphotericin either twice or 3 times daily has been effective to prevent Aspergillus infection. Nebulized amphotericin twice daily may be a more viable option to increase a patient's adherence and decrease medication cost and side effects. However, a larger randomized controlled trial is needed to determine the best dosing regimen for nebulized amphotericin B as a fungal prophylaxis after lung transplant.